BLUE Projected Dividend Yield

bluebird bio Inc ( NASDAQ : BLUE )

bluebird bio is a biotechnology company focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector gene addition platform. Co. has two gene therapies: ZYNTEGLO® (betibeglogene autotemcel, also known as beti-cel) and SKYSONA® (elivaldogene autotemcel, also known as eli-cel). ZYNTEGLO is for the treatment of adult and pediatric patients with B-thalassemia who require regular red blood cell transfusions. SKYSONA is for slowing the progression of neurologic dysfunction in boys four to 17 years of age with early active cerebral adrenoleukodystrophy.

20 YEAR PERFORMANCE RESULTS